1. Home
  2. TBPH vs HPP Comparison

TBPH vs HPP Comparison

Compare TBPH & HPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • HPP
  • Stock Information
  • Founded
  • TBPH 2013
  • HPP 2009
  • Country
  • TBPH United States
  • HPP United States
  • Employees
  • TBPH N/A
  • HPP N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • HPP Real Estate
  • Sector
  • TBPH Health Care
  • HPP Finance
  • Exchange
  • TBPH Nasdaq
  • HPP Nasdaq
  • Market Cap
  • TBPH 464.5M
  • HPP 453.1M
  • IPO Year
  • TBPH N/A
  • HPP 2010
  • Fundamental
  • Price
  • TBPH $9.01
  • HPP $3.08
  • Analyst Decision
  • TBPH Buy
  • HPP Hold
  • Analyst Count
  • TBPH 4
  • HPP 10
  • Target Price
  • TBPH $13.75
  • HPP $3.43
  • AVG Volume (30 Days)
  • TBPH 192.5K
  • HPP 2.6M
  • Earning Date
  • TBPH 05-12-2025
  • HPP 05-07-2025
  • Dividend Yield
  • TBPH N/A
  • HPP 1.65%
  • EPS Growth
  • TBPH N/A
  • HPP N/A
  • EPS
  • TBPH N/A
  • HPP N/A
  • Revenue
  • TBPH $64,381,000.00
  • HPP $834,774,000.00
  • Revenue This Year
  • TBPH $51.09
  • HPP N/A
  • Revenue Next Year
  • TBPH N/A
  • HPP $5.63
  • P/E Ratio
  • TBPH N/A
  • HPP N/A
  • Revenue Growth
  • TBPH 12.12
  • HPP N/A
  • 52 Week Low
  • TBPH $7.44
  • HPP $2.39
  • 52 Week High
  • TBPH $10.90
  • HPP $6.69
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 41.82
  • HPP 54.64
  • Support Level
  • TBPH $8.72
  • HPP $2.82
  • Resistance Level
  • TBPH $9.55
  • HPP $3.27
  • Average True Range (ATR)
  • TBPH 0.25
  • HPP 0.19
  • MACD
  • TBPH -0.04
  • HPP 0.02
  • Stochastic Oscillator
  • TBPH 34.94
  • HPP 68.55

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About HPP Hudson Pacific Properties Inc.

Hudson Pacific Properties Inc is a real estate investment trust that acquires, operates, and owns office buildings and media and entertainment properties, such as sound stages, on America's West Coast. The company focuses on developed, urban markets in Northern California, Southern California, and the Pacific Northwest. In terms of total square footage, the vast majority of Hudson Pacific's real estate portfolio is composed of office properties located in the Greater Seattle, San Francisco, and Los Angeles areas. The company operates in two reportable segments; office properties & related operations; and studio properties & related operations. The majority of revenue is derived from the office properties & related operations segment.

Share on Social Networks: